This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

William D. Dupont, PhD; David L. Page, MD

Arch Intern Med. 1991;151(1):67-72.

Abstract
We conducted a meta-analysis of the literature concerning breast cancer and estrogen replacement therapy. The overall relative risk of breast cancer associated with this therapy was 1.07. However, the variation of the estimated risks among the studies was far greater than could plausibly be explained by chance alone. To explain this variation, we looked at the effects of type, duration, and dosage of treatment. Overall, women who took 0.625 mg/d or less of conjugated estrogens had a risk of breast cancer that was 1.08 times that of women who did not receive this therapy (95% confidence interval [CI], 0.96 to 1.2). The relative risks from these individual studies of low-dosage therapy did not differ significantly from each other. Women who took 1.25 mg/d or more of conjugated estrogens had a breast cancer relative risk of 2.0 or less in all studies. However, the variation in observed risks at this higher dosage was significant. This implies that other risk factors varied among these studies, making it difficult to estimate the overall risk associated with this dosage. The relative risk of breast cancer associated with estro gen replacement therapy among women with a history of benign breast disease was 1.16 (95% CI, 0.89 to 1.5). The combined results from multiple studies provide strong evidence that meno pausal therapy consisting of 0.625 mg/d or less of conjugated estrogens does not increase breast cancer risk.

(Arch Intern Med. 1991;151:67-72)

Author Affiliations
From the Departments of Preventive Medicine (Dr Dupont) and Pathology (Dr Page), Vanderbilt University School of Medicine, Nashville, Tenn.

Footnotes
Accepted for publication November 2, 1990.

Reprint requests to Department of Preventive Medicine, A-1128 Medical Center North, Vanderbilt University School of Medicine, Nashville, TN 37232-2637 (Dr Dupont).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

G Protein-Coupled Receptor 30 Expression Is Up-Regulated by EGF and TGF{alpha} in Estrogen Receptor {alpha}-Positive Cancer Cells
Vivacqua et al.
Mol. Endocrinol. 2009;23:1815-1826.
ABSTRACT | FULL TEXT  

Commentary: Hormone therapy and breast cancer incidence: did epidemiologists miss an effect on national trends?
Paul
Int J Epidemiol 2008;37:638-640.
FULL TEXT  

The G Protein-Coupled Receptor GPR30 Mediates the Proliferative Effects Induced by 17{beta}-Estradiol and Hydroxytamoxifen in Endometrial Cancer Cells
Vivacqua et al.
Mol. Endocrinol. 2006;20:631-646.
ABSTRACT | FULL TEXT  

Menopausal hormone therapy and risk of breast cancer: a meta-analysis of epidemiological studies and randomized controlled trials
Greiser et al.
Hum Reprod Update 2005;11:561-573.
ABSTRACT | FULL TEXT  

Peptide Binding Identifies an ER{alpha} Conformation That Generates Selective Activity in Multiple In Vitro Assays
Larson et al.
J Biomol Screen 2005;10:590-598.
ABSTRACT  

Effects of Conjugated Equine Estrogen in Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative Steering Committee
JAMA 2004;291:1701-1712.
ABSTRACT | FULL TEXT  

Postmenopausal Hormone Replacement Therapy: Scientific Review
Nelson et al.
JAMA 2002;288:872-881.
ABSTRACT | FULL TEXT  

Why Do We Still Use Hormone Replacement Therapy? Why Don't We Use It More?
Vogel
JCO 2002;20:616-619.
FULL TEXT  

Comparative Analyses of Mechanistic Differences Among Antiestrogens
Wijayaratne et al.
Endocrinology 1999;140:5828-5840.
ABSTRACT | FULL TEXT  

Risk of breast cancer associated with hormone replacement therapy
Dopp and Kolesar
J Oncol Pharm Pract 1999;5:109-116.
ABSTRACT  

LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34)
Sato et al.
Endocrinology 1998;139:4642-4651.
ABSTRACT | FULL TEXT  

LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo
Sato et al.
J. Pharmacol. Exp. Ther. 1998;287:1-7.
ABSTRACT | FULL TEXT  

The Critical Role of Alcohol Consumption in Determining the Risk of Breast Cancer with Postmenopausal Estrogen Administration
Zumoff
J. Clin. Endocrinol. Metab. 1997;82:1656-1658.
FULL TEXT  

Bone Mass and the Risk of Breast Cancer among Postmenopausal Women
Zhang et al.
NEJM 1997;336:611-617.
ABSTRACT | FULL TEXT  

Rationale for Estrogen With Interrupted Progestin as a New Low-Dose Hormonal Replacement Therapy
Casper et al.
Reproductive Sciences 1996;3:225-234.
ABSTRACT  

Hormone Replacement Therapy and Breast Cancer Risk
Gambrell
Arch Fam Med 1996;5:341-348.
ABSTRACT  

Hormone Replacement and Breast Cancer: A Remaining Controversy?
Adami and Persson
JAMA 1995;274:178-179.
ABSTRACT  

Estrogen Replacement Therapy in Breast Cancer Survivors: A Time for Change
Cobleigh et al.
JAMA 1994;272:540-545.
ABSTRACT  

Hormonal Treatment of Postmenopausal Women
Belchetz
NEJM 1994;330:1062-1071.
FULL TEXT  

Coronary Artery Disease in Women: Risk Factors, Evaluation, Treatment, and Prevention
Kuhn and Rackley
Arch Intern Med 1993;153:2626-2636.
ABSTRACT  

Low Levels of High-Density Lipoprotein Cholesterol (Hypoalphalipoproteinemia) An Approach to Management
Rosenson
Arch Intern Med 1993;153:1528-1538.
ABSTRACT  

The Postmenopausal Estrogen/Breast Cancer Controversy
Grady and Rubin
JAMA 1993;269:990-990.
ABSTRACT  

Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women
Grady et al.
ANN INTERN MED 1992;117:1016-1037.
ABSTRACT  

The Postmenopausal Estrogen/Breast Cancer Controversy
Henrich
JAMA 1992;268:1900-1902.
ABSTRACT  

General Internal Medicine
Stoeckle and Goodson
JAMA 1992;268:358-360.
ABSTRACT  

Estrogen Therapy for Osteoporosis--Even in the Elderly
Ott
ANN INTERN MED 1992;117:85-86.
ABSTRACT  

Results of Bone Densitometry Affect Women's Decisions about Taking Measures To Prevent Fractures
Rubin and Cummings
ANN INTERN MED 1992;116:990-995.
ABSTRACT  

Estrogen Replacement Therapy and Risk of Breast Cancer: Results of Two Meta-analyses
Vasan
Arch Intern Med 1992;152:1090-1090.
ABSTRACT  

Estrogen Replacement Therapy and Risk of Breast Cancer: Results of Two Meta-analyses-Reply
Dupont and Page
Arch Intern Med 1992;152:1090-1093.
ABSTRACT  

Estrogens and Breast Cancer
Atkins
Arch Intern Med 1991;151:1882-1882.
ABSTRACT  

Estrogens and Breast Cancer-Reply
Dupont and Page
Arch Intern Med 1991;151:1882-1884.
ABSTRACT  

Estrogens and Disease Prevention
Moon
Arch Intern Med 1991;151:17-18.
ABSTRACT